Beam Therapeutics, Inc. (BEAM)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$24.05-2.08%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Beam Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	10.13M
EPS	—	-1.181
Annual ending 2026-12-31
Revenue	—	51.24M
EPS	—	-4.433
Annual ending 2027-12-31
Revenue	—	63.83M
EPS	—	-4.806

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance and expand base editing product pipeline	Beam is advancing its gene editing portfolio with strong trial data.	Intact	Failure to report meaningful progress or trial setbacks by end 2026	Qualitative progress confirmed (BEAM-302 data) vs 2026 target Sept 2026 news reports updated Phase 1/2 data for BEAM-302, reinforcing clinical development progress in the base editing portfolio. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses	Operating losses are being managed with some progress.	Under Pressure	Operating losses worsen beyond -$110M per quarter over next 4 quarters	Operating income: $-126.553M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$107M in Q1 2026 and improving thereafter. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-126,553,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: e84f6a19-0bd1-4c4d-a188-52d3268b9e9c. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Limit revenue decline	A supporting condition in Beam Therapeutics, Inc.'s published investment case. The stated target is Revenue decline less than -35% in 2026.	Intact	Revenue decline exceeds -40% in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Secure financing to cover expenses into 2029	It aims to secure financing through 2029.	Intact	Failure to secure or maintain financing covering expenses beyond 2027	Qualitative: $500M facility secured Beam entered a $500M financing agreement with Sixth Street Lending Partners on Feb 24, 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.81

$-4.73 → $-4.81 · observed estimates

FY2027 revenue$0.06B

$0.10B → $0.06B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-4.73	$96,069,740	11 / 12
2026-07-25	$-4.73	$96,069,740	11 / 12
2026-07-26	$-4.73	$96,069,740	11 / 12
2026-07-27	$-4.73	$96,069,740	11 / 12
2026-07-28	$-4.73	$96,069,740	11 / 12
2026-07-29	$-4.73	$96,069,740	11 / 12
2026-07-30	$-4.73	$96,069,740	11 / 12
2026-07-31	$-4.55	$92,118,085	9 / 9
2026-08-01	$-4.73	$96,069,740	11 / 12
2026-08-02	$-4.73	$96,069,740	11 / 12
2026-08-03	$-4.73	$96,069,740	11 / 12
2026-08-04	$-4.73	$96,069,740	11 / 12
2026-08-05	$-4.73	$96,069,740	11 / 12
2026-08-06	$-4.71	$91,793,690	12 / 10
2026-08-07	$-4.66	$64,334,669	9 / 8
2026-08-08	$-4.71	$91,793,690	12 / 10
2026-08-09	$-4.63	$73,089,580	13 / 11
2026-08-10	$-4.63	$73,089,580	13 / 11
2026-08-11	$-4.74	$62,748,780	12 / 12
2026-08-12	$-4.74	$62,748,780	12 / 12
2026-08-13	$-4.74	$62,748,780	12 / 12
2026-08-14	$-4.66	$64,334,669	9 / 8
2026-08-15	$-4.66	$64,334,669	9 / 8
2026-08-16	$-4.66	$64,334,669	9 / 8
2026-08-17	$-4.66	$64,334,669	9 / 8
2026-08-18	$-4.66	$64,334,669	9 / 8
2026-08-19	$-4.66	$64,334,669	9 / 8
2026-08-20	$-4.74	$56,048,954	9 / 9
2026-08-21	$-4.74	$56,048,954	9 / 9
2026-08-22	$-4.74	$56,048,954	9 / 9
2026-08-23	$-4.74	$56,048,954	9 / 9
2026-08-24	$-4.74	$56,048,954	9 / 9
2026-08-25	$-4.74	$56,048,954	9 / 9
2026-08-26	$-4.74	$56,048,954	9 / 9
2026-08-27	$-4.74	$56,048,954	9 / 9
2026-08-28	$-4.74	$56,048,954	9 / 9
2026-08-29	$-4.74	$56,048,954	9 / 9
2026-08-30	$-4.74	$56,048,954	9 / 9
2026-08-31	$-4.74	$56,048,954	9 / 9
2026-09-01	$-4.74	$56,048,954	9 / 9
2026-09-02	$-4.74	$56,048,954	9 / 9
2026-09-03	$-4.79	$56,048,954	9 / 9
2026-09-04	$-4.79	$56,048,954	9 / 9
2026-09-05	$-4.79	$56,048,954	9 / 9
2026-09-06	$-4.79	$56,048,954	9 / 9
2026-09-07	$-4.79	$56,048,954	9 / 9
2026-09-08	$-4.79	$56,048,954	9 / 9
2026-09-09	$-4.79	$56,070,390	9 / 9
2026-09-10	$-4.79	$63,834,676	9 / 9
2026-09-11	$-4.79	$63,834,676	9 / 9
2026-09-12	$-4.79	$63,834,676	9 / 9
2026-09-13	$-4.79	$63,834,676	9 / 9
2026-09-14	$-4.79	$63,834,676	9 / 9
2026-09-15	$-4.79	$63,834,676	9 / 9
2026-09-16	$-4.79	$63,834,676	9 / 9
2026-09-17	$-4.79	$63,834,676	9 / 9
2026-09-18	$-4.79	$63,834,676	9 / 9
2026-09-19	$-4.79	$63,834,676	9 / 9
2026-09-20	$-4.79	$63,834,676	9 / 9
2026-09-21	$-4.79	$63,834,676	9 / 9
2026-09-22	$-4.79	$63,834,676	9 / 9
2026-09-23	$-4.79	$63,834,676	9 / 9
2026-09-24	$-4.79	$63,834,676	9 / 9
2026-09-25	$-4.79	$63,834,676	9 / 9
2026-09-26	$-4.79	$63,834,676	9 / 9
2026-09-27	$-4.79	$63,834,676	9 / 9
2026-09-28	$-4.79	$63,834,676	9 / 9
2026-09-29	$-4.79	$63,834,676	9 / 9
2026-09-30	$-4.79	$63,834,676	9 / 9
2026-10-01	$-4.79	$63,834,676	9 / 9
2026-10-02	$-4.79	$63,834,676	9 / 9
2026-10-03	$-4.79	$63,834,676	9 / 9
2026-10-04	$-4.79	$63,834,676	9 / 9
2026-10-05	$-4.79	$63,834,676	9 / 9
2026-10-06	$-4.79	$63,834,676	9 / 9
2026-10-07	$-4.79	$63,834,676	9 / 9
2026-10-08	$-4.79	$63,834,676	9 / 9
2026-10-09	$-4.79	$63,834,676	9 / 9
2026-10-10	$-4.79	$63,834,676	9 / 9
2026-10-11	$-4.79	$63,834,676	9 / 9
2026-10-12	$-4.79	$63,834,676	9 / 9
2026-10-13	$-4.79	$63,834,676	9 / 9
2026-10-14	$-4.79	$63,834,676	9 / 9
2026-10-15	$-4.79	$63,834,676	9 / 9
2026-10-16	$-4.79	$63,834,676	9 / 9
2026-10-17	$-4.79	$63,834,676	9 / 9
2026-10-18	$-4.79	$63,834,676	9 / 9
2026-10-19	$-4.79	$63,834,676	9 / 9
2026-10-20	$-4.79	$63,834,676	9 / 9
2026-10-21	$-4.79	$63,834,676	9 / 9
2026-10-22	$-4.79	$63,834,676	9 / 9
2026-10-23	$-4.81	$63,834,676	10 / 9
2026-10-24	$-4.81	$63,834,676	10 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	15	2
2026-06-01	15	2
2026-07-01	15	2
2026-08-01	13	2
2026-09-01	13	2
2026-10-01	13	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage operating lossesPublished status: Under Pressure
Limit revenue declineDirect metric needs a verified mapping

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-39.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Beam Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

BEAM is a speculative, clinical-stage biotechnology business, not an established earnings compounder. Its thesis state is watch: programs are advancing, but recent financial performance is weak and the business is loss-making.

What's priced into Beam Therapeutics, Inc.

BEAM carries a durable premium versus peers, and the evidence labels that premium unjustified. The expectations gap is 0.8, with medium model confidence, but the snapshot does not say exactly which future outcomes market expectations assume.

What the fundamentals likely do

Over the near term, earnings risk is elevated after the latest quarter missed and recent surprises have been erratic. Management has made progress on BEAM-302, risto-cel, and BEAM-304, but each priority is rated mixed, so clinical and regulatory execution remains important. The Healthcare sector backdrop has strengthened, though weaker employment could raise recession concerns across the sector.

What Beam Therapeutics, Inc. hinges on

The multi-year thesis depends on continued clinical progress, including the planned risto-cel regulatory submission by year-end 2026 and further BEAM-302 and BEAM-304 milestones. A guidance cut or another weak earnings result would add to near-term concerns. Strong results and guidance from Healthcare bellwethers could support sector momentum, while weakening employment could weigh on the sector.